About Dr. Fein
Adam J. Fein, Ph.D., is the president of Pembroke Consulting, Inc., a management advisory and business research firm based in Philadelphia. He also is the CEO of Pembroke’s Drug Channels Institute, a leading management educator for and about the pharmaceutical industry.
Dr. Fein is one of the country’s foremost experts on pharmaceutical economics and the drug distribution system. Top manufacturers call on Dr. Fein’s insights and judgment, to create successful commercial strategies and make better strategic decisions in our evolving healthcare environment.
Dr. Fein’s popular and influential Drug Channels blog is the go-to source for definitive and comprehensive industry analysis, delivered with a witty edge. He has published hundreds of academic and industry articles, and is regularly quoted in such national publications as The Wall Street Journal, The New York Times, Fortune, Drug Benefit News, and many others.
Dr. Fein also is a popular speaker. He inspires his audiences to think strategically with content-rich and entertaining keynote presentations.
Dr. Fein earned his doctoral degree from the Wharton School of Business at the University of Pennsylvania and a B.A., summa cum laude, from Brandeis University. He lives in Philadelphia with his wife and their two children.
Dr. Fein in the News
Judge Dismisses Hospital-Industry Suit That Attempted to Stop Medicare-Subsidy Cuts The Wall Street Journal
What should Walgreens do now? Crain's Chicago Business
How Will Consumers Fare if CVS and Aetna Merge? The New York Times
What The CVS And Aetna Merger Has To Do With Amazon National Public Radio
Fighting for the Specialty Market & Patient Journey Specialty Pharmacy Continuum
Experts: We Can Lower Drug Prices RealClearPolitics
Trump’s pick to lower drug prices is a former pharma executive who raised them The Washington Post
CVS adds next-day prescription delivery as threat of Amazon competition looms The Washington Post
Amazon’s Push Into Pharmacy Business Is Full of Promise and Pitfalls The Wall Street Journal
Questions swirl about Amazon's intentions in prescription drug business St. Louis Post-Dispatch